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Abstract 
Background: Understanding mid-term kinetics of immunity to SARS-CoV-2 is the 
cornerstone for public health control of the pandemic and vaccine development. 
However, current evidence is rather based on limited measurements, losing sight of the 
temporal pattern of these changes.  
Methods: We conducted a longitudinal analysis on a prospective cohort of COVID-19 
patients followed up to 242 days. Neutralizing activity was evaluated using  HIV reporter 
pseudoviruses expressing SARS-CoV-2 S protein. IgG antibody titer was evaluated by 
ELISA against the S2 subunit, the receptor binding domain (RBD) and the nucleoprotein 
(NP). Statistical analyses were carried out using mixed-effects models.  
Findings: We found that individuals with mild or asymptomatic infection experienced 
an insignificant decay in neutralizing activity, which persisted six months after symptom 
onset or diagnosis. Hospitalized individuals showed higher neutralizing titers, which 
decreased following a two-phase pattern, with an initial rapid decline that significantly 
slowed after day 80. Despite this initial decay, neutralizing activity at six months 
remained higher among hospitalized individuals compared to mild symptomatic. The 
slow decline in neutralizing activity at mid-term contrasted with the steep slope of 
anti-RBD, S2 or NP antibody titers, all of them showing a constant decline over the 
follow-up period.  
Conclusions: Our results reinforce the hypothesis that the quality of the neutralizing 
immune response against SARS-CoV-2 evolves over the post-convalescent stage. 
Keywords 
SARS-CoV-2, humoral response, pseudovirus, neutralization, durability.   
 3 
Introduction 
While the early humoral response after SARS-CoV-2 infection has been thoroughly 
described 1–5, current data on the decay of antibody levels beyond the convalescent stage 
depict a heterogeneous scenario with limited information on the neutralizing activity 
throughout the follow-up period 6–8. Various authors have recently suggested more 
complex kinetics of neutralizing activity decay as compared to total antibody titers, with 
clonotype-, epitope-, or subject-specific patterns that evolve in terms of potency and 
resistance to epitope mutations 9–11. In this study, we longitudinally evaluated the 
neutralizing humoral response, in mild/asymptomatic and hospitalized individuals 
infected by SARS-CoV-2, over a 6-month period. These mid-term kinetics showed in 
both groups, a stable behavior of the neutralizing response despite a clear decrease of the 
total viral specific humoral response. 
  
 4 
Results and Discussion 
Our analysis included 210 patients with RT-PCR-confirmed SARS-CoV-2 infection, 
recruited during the first and second waves of the COVID-19 epidemic in Catalonia 
(North-East Spain). Of them, 106 (50.5%) had a mild or asymptomatic infection, and 104 
(49.5%) required hospitalization because of respiratory compromise (Table 1). We 
collected samples periodically throughout a maximum follow-up period of 242 days 
(Figure S1, Supplementary Material). Most study participants developed a neutralizing 
humoral response against SARS-CoV-2 HIV-based pseudoviruses, that was confirmed 
using infectious viruses. However, in line with trends reported elsewhere7,8, mildly 
affected or asymptomatic individuals developed a 10-fold lower maximal neutralization 
titer than those who required hospitalization when the full dataset was analyzed 
(p<0.0001, Mann-Whitney test; Fig. 1a). The higher number of determinations obtained 
from hospitalized individuals during the acute phase permitted the clear observation of a 
sharp initial response (Fig. 1b-c), also reported in previous analyses of the early 
response1–5. This was visible for individuals recruited during both the first (March-June 
2020) and the second (July-October 2020) waves of COVID-19 pandemic in Catalonia. 
A longitudinal analysis fitted to a four-parameter logistic model of increase defined a 30-
day sharpening phase after symptom onset, irrespective of the wave in which hospital 
admission occurred. Half maximal neutralization activity was achieved on day 10 (95% 
confidence interval, CI 8-11); 80% maximal response, which corresponded to 3.97 logs 
(i.e., 9,333 reciprocal dilution), was achieved on day 14 (Fig. 1d). Based on this finding, 
we assumed no significant differences between the two waves regarding early 
neutralizing response and we decided to set day 30 after symptom onset as a starting point 
for the longitudinal analysis of immune response at the mid-term.  
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The longitudinal modeling of the neutralizing activity at mid-term in our cohort revealed 
a nearly flat slope (i.e., not significantly different from 0, with half-life 2134 days) in 
individuals with asymptomatic infection or mild disease (Fig. 2a). Conversely, the 
decrease of neutralizing activity in hospitalized individuals showed a two-phase pattern, 
with a rapid decay (half-life 31 days) until day 80 that slowed down to a flat slope (half-
life 753 days) from that time point on (Fig. 2b).  
The characterization of the neutralizing activity behavior at mid-term should ultimately 
project the proportion of post-convalescent individuals protected against new infections 
in the mid- and long-term. The limited number of measures and lack of a clear threshold 
of neutralizing activity for preventing SARS-CoV-2 infection precluded assessing this 
outcome using survival analysis. Alternatively, we explored the neutralizing activity at 
the end of our 6-month follow-up period. Based on the mixed-effects model obtained 
from the longitudinal analysis, we estimated a stable mid-term neutralizing activity of 
2.72 and 3.16 log for the mild/asymptomatic and hospitalized subgroups, respectively 
(p<0.0001; likelihood ratio test, Fig. 2c, dotted lines). This estimate was consistent with 
the observed values for the last measurement taken between days 135 and 242, a time 
frame centered on day 180 (Fig. 2c, box plots). Likewise, the value distribution at this 
time frame showed significant differences between mild/asymptomatic (median 2.5; IQR 
2.0–3.0) and hospitalized (3.0; 2.7–3.3) individuals (p=0.0012, Mann-Whitney test). To 
date, no clear cut-off for a neutralizing activity that protects against new reinfection has 
been established. Nevertheless, data gathered from high attack rate events suggest that 
neutralizing activities between 1:161 and 1:3,082 are strong enough to prevent 
infection12. Hence, we assumed that reinfections would be unlikely among individuals 
above the 1:250 cut-off. Of the 23 hospitalized individuals with measurement beyond day 
135, 21 (91%) had a mean neutralizing activity value above 1:250 and were thus 
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considered long-term neutralizers. The corresponding proportion in the 
mild/asymptomatic group (42%; 19/45) was significantly lower (p=0.0052, Chi-square 
test, Fig. 2d). Although this number must be taken cautiously due to the cut-off 
assumption, our finding suggests that hospitalized patients have a higher capacity for 
long-term neutralization, despite the faster initial decay in neutralization activity. 
It has recently been proposed that the kinetics of neutralizing activity may not mirror 
those of antibody titers9. Hence, we investigated the change in IgG titers in a subset of 28 
individuals (14 in each severity group) with the most extended follow-up period. The 
analysis included antibodies against the receptor-binding domain (RBD) and S2 subunit 
of the S protein, both associated with potential neutralizing activity; and the nucleoprotein 
(NP), which are very abundant, albeit unable to neutralize the SARS-CoV-213. The 
longitudinal analysis revealed a one-phase significant (p<0.0001) steady decay pattern of 
all tested antibodies, which was notably faster in anti-NP IgG (Fig. 3a-c). The half-life of 
anti-RBD, anti-S2, and anti-NP antibodies for the period beyond day 30 were 86, 108, 
and 59 days, respectively. These values were consistent with those reported by Wheatley 
et al., estimated on a 160-day time frame9. Although the limited sample size of this sub-
analysis precluded independent modeling of the decay in mild/asymptomatic and 
hospitalized patients, the latter showed significantly higher titers of anti-S2 at the end of 
the follow-up period (Figure S2), whereas no significant differences were found in other 
antibodies regarding disease status. Interestingly, in this subset of individuals, the decay 
in antibody titers contrasted with the behavior of neutralizing activity, which fitted to a 
two-phase model―as in the whole dataset―with a rapid decay until day 80 (slope 0.014, 
half-life 22 days) and a flat slope (i.e., not significantly different from 0) afterward (Fig. 
3d).  
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Complementary data on the binding affinity and B-cell clone abundance at the same time 
points would provide a more comprehensive picture to explain this divergent trend. 
However, our findings support the hypothesis of Gaebler et al., who suggested that the 
accumulation of IgG somatic mutations―and subsequent production of antibodies with 
increased neutralizing potency―allow the maintenance of neutralizing activity levels, 
despite the decline in specific antibody titers11. Of note, our follow-up period 
encompassed two waves of the COVID-19 outbreak in our country. Individuals infected 
during the first wave were likely to be exposed to high viral pressure in their environment, 
potentially favoring further virus exposure that may also contribute to boosting humoral 
responses, adding to the mechanism proposed by Gaebler et al11. 
Our analysis is limited by the reduced sample size, particularly in the mild/asymptomatic 
subgroup, for which we failed to identify a two-phase pattern decay of neutralizing 
activity. Despite the limited sample size, the availability of multiple measures along the 
follow-up period allowed us to provide a longitudinal perspective on neutralizing activity, 
and antibody titer behavior. This analysis supplements current evidence regarding mid-
term immunity against SARS-CoV-27,9,11. Our longitudinal analysis confirmed the slow 
decay and mid-term maintenance of neutralizing activity observed in other cohorts with 
a 5-to-11% prevalence of hospitalized patients7,11. In this regard, the two-phase 
behavioral pattern of neutralizing activity observed in hospitalized individuals suggests 
that the rapid decay reported in previous characterizations6 might be due to the abundance 
of individuals in this early phase. Furthermore, apparent inconsistencies found between 
the declines of neutralizing activity and IgG titers reinforce the idea proposed by other 
authors that the behavior of antibody titers may not mirror the neutralizing activity. Taken 
together, current evidence on immunity to SARS-CoV-2 infection suggests stability of 
neutralizing activity, pointing towards an optimistic scenario for the establishment of 
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infection- or vaccine-mediated herd immunity. Still, long-term data available on other 
human coronaviruses show waning of antibodies 1-to-2 years after infection14,15, with 
uncertainty regarding the immune response behavior in the context of vaccine-mediated 
immunity16. The continuity of our prospective cohort of individuals recovered from 




Study overview and subjects 
The study was approved by the Hospital Ethics Committee Board from Hospital 
Universitari Germans Trias i Pujol (PI-20-122 and PI-20-217) and all participants 
provided written informed consent before inclusion. 
Plasma samples were obtained from individuals of the prospective KING cohort of the 
HUGTiP (Badalona, Spain). The recruitment period lasted from March to October 2020, 
thus covering the first and second waves of COVID-19 outbreak in Catalonia 
(dadescovid.cat). The KING cohort included individuals with a documented positive RT-
qPCR result from nasopharyngeal swab and/or a positive serological ELISA test 
performed in our hospital, irrespective of age and disease severity―including 
asymptomatic status. Individuals were recruited in various settings, including primary 
care, hospital, and epidemiological surveillance based on contact tracing. We collected 
plasma samples at the time of COVID-19 diagnosis and at 3 and 6 months. Additionally, 
hospitalized individuals were sampled twice a week during the acute phase.  
Humoral response determination  
The humoral response against SARS-CoV-2 was evaluated with an in-house sandwich- 
ELISA using the following antigens (Sino Biological, Germany): S2 (Ser686-Pro1213), 
RBD (Arg319-Phe541), and whole nucleocapsid protein (NP). Nunc MaxiSorp plates 
were coated with 50 µL of anti-6x-His antibody clone HIS.H8 (2 µg/mL, Thermo Fisher 
Scientific, USA) in PBS overnight at 4ºC. After washing, plates were blocked with 1% 
BSA in PBS (Miltenyi Biotec, Germany) for two hours at room temperature. Antigens 
were added at 1 µg/mL concentration (50 µL/well) and incubated overnight at 4ºC. 
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Plasma samples were heat-inactivated before use (56ºC for 30 minutes) and analyzed in 
duplicate in antigen-coated and antigen-free wells in the same plate. Serial dilutions of a 
positive plasma sample were used as standard. A pool of pre-pandemic plasmas from 
healthy controls was used as a negative control. Standards, negative control, and plasma 
samples were diluted in blocking buffer and were incubated (50 µL/well) for one hour at 
room temperature. The HRP-conjugated (Fab)2 goat anti-human IgG (Fc specific, 
Jackson ImmunoResearch, UK) was then incubated for 30 minutes at room temperature. 
Plates were revealed with o-Phenylenediamine dihydrochloride (Sigma-Aldrich, USA) 
and reaction was stopped using 4N of H2SO4 (Sigma-Aldrich). Optical density (OD) at 
492 nm with noise correction at 620 nm were used to calculate specific signal for each 
antigen after subtracting the antigen-free well signal for each sample. Standard curves 
were fitted to a 5-parameter logistic curve and data was expressed as arbitrary units (AU) 
according to the standard. 
Pseudovirus generation and neutralization assay 
HIV reporter pseudoviruses expressing SARS-CoV-2 S protein and Luciferase were 
generated. pNL4-3.Luc.R-.E- was obtained from the NIH AIDS Reagent Program17. 
SARS-CoV-2.SctΔ19 was generated (GeneArt) from the full protein sequence of SARS-
CoV-2 spike with a deletion of the last 19 amino acids in C-terminal18, human-codon 
optimized and inserted into pcDNA3.4-TOPO. Expi293F cells were transfected using 
ExpiFectamine293 Reagent (Thermo Fisher Scientific) with pNL4-3.Luc.R-.E- and 
SARS-CoV-2.SctΔ19 at a 24:1 ratio, respectively. Control pseudoviruses were obtained 
by replacing the S protein expression plasmid with a VSV-G protein expression plasmid 
as reported19. Supernatants were harvested 48 hours after transfection, filtered at 0.45 µm, 
 11 
frozen, and titrated on HEK293T cells overexpressing WT human ACE-2 (Integral 
Molecular, USA). 
Neutralization assays were performed in duplicate. Briefly, in Nunc 96-well cell culture 
plates (Thermo Fisher Scientific), 200 TCID50 of pseudovirus were preincubated with 
three-fold serial dilutions (1/60–1/14,580) of heat-inactivated plasma samples for 1 hour 
at 37ºC. Then, 2x104 HEK293T/hACE2 cells treated with DEAE-Dextran (Sigma-
Aldrich) were added. Results were read after 48 hours using the EnSight Multimode Plate 
Reader and BriteLite Plus Luciferase reagent (PerkinElmer, USA). The values were 
normalized, and the ID50 (the reciprocal dilution inhibiting 50% of the infection) was 
calculated by plotting and fitting the log of plasma dilution vs. response to a 4-parameters 
equation in Prism 8.4.3 (GraphPad Software, USA).  
Statistical analysis 
Continuous variables were described using medians and the interquartile range (IQR, 
defined by the 25th and 75th percentiles), whereas categorical factors were reported as 
percentages over available data. Quantitative variables were compared using the Mann-
Whitney test, and percentages using the chi-squared test. Kinetics of neutralizing activity 
and antibody titers were estimated from symptom onset―or serological diagnosis in 
asymptomatic individuals―and modeled using mixed-effects models and in two steps. 
First, a 4-parameter logistic function was adjusted for the first 30 days after diagnosis 
using non-linear mixed models. Mid-term decay was analyzed using a piecewise 
regression with two decline slopes for data beyond 30 days, with a breakpoint at 80 days. 
For the latter analysis, linear mixed-effect models with random intercepts and slopes were 
used, and different breakpoints were tested; the best fit was chosen. For the longitudinal 
analysis of neutralizing activity, patients were grouped into two severity groups according 
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to the WHO progression scale20: asymptomatic or mild (levels 1-3), and hospitalized 
(levels 4-10). Differences between the two severity groups were assessed using the 
likelihood ratio test. The longitudinal analysis of antibody titers was performed on a 
subset of 28 individuals (14 in each severity group) with the highest number of measures 
during the follow-up; owing to the limited sample size, all individuals were analyzed as 
a single group. Analyses were performed with Prism 8.4.3 (GraphPad Software) and R 
version 4.0 (R Foundation for Statistical Computing). Mixed-effects models were fitted 
using “nlme” R package.  
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Fig 1. Neutralizing activity among study participants. a, Maximal neutralization titer 
of 210 individuals recruited, according to disease severity (light and dark blue for 
mild/asymptomatic and hospitalized individuals, respectively). Boxes show the median 
and the interquartile range, and bars the 10th and 90th percentiles. Distributions were 
compared using the Mann-Whitney test. Individual values are ranked for comparative 
purposes. b and c, Longitudinal dot plot of neutralizing activity among hospitalized 
individuals admitted during the first (b) and second (c) waves of the COVID-19 epidemic 
in our area; filled (b) and empty (c) blue dots show the early (i.e., 30 days after diagnosis) 
increasing phase. d, Magnification of the early phase for individuals admitted during the 
first (filled symbols) and second (empty symbols) waves. No differences between waves 
were observed. The solid line shows the non-linear fit (mixed-model estimate) for the 
whole dataset (125 samples, 55 individuals analyzed). Two samples from late 
seroconverters (one from each wave, grey dots) were excluded from the analysis. 
Fig. 2. Longitudinal analysis of neutralizing activity. a, Individual measurements 
(dots) and linear mixed model (solid orange line) of the longitudinal analysis for mild or 
asymptomatic individuals beyond day 30 (single-phase slope -0.00014; p=0.75, 
likelihood ratio test; estimated half-life 2,134 days). Time points preceding day 30 as well 
as participants only showing undetectable titers were excluded from the analysis, values 
are shown but grayed out. b, the corresponding analysis for hospitalized individuals (the 
slopes of the linear fit for the first and second phase were -0.0096 [p=0.0002] [half-life 
31 days] and -00004 [half-life 753 days] [p=0.78], respectively). c, Distribution of 
neutralizing activity six months after infection in both disease severity groups. 
Experimental values of mean neutralizing activities in the period 135-to-242 days as 
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summarized in box-plots (as in Figure 1a; Mann-Whitney test for comparative analysis) 
and modeled data as dotted lines (likelihood ratio test for comparative analysis). d, 
Frequency of long-term neutralizers (i.e., individuals with mean neutralizing activity 
>250 in the 135-242 days period) in each severity subgroup (Chi square test p value is 
shown).  
Fig. 3. Longitudinal analysis of IgG titers. a, anti-receptor binding domain (RBD). b, 
anti-S2. c, anti-nucleoprotein. d, overall neutralizing activity in the same set of samples. 
All analyses were performed on a subset of individuals with largest follow-up (n=14 for 
mild/asymptomatic in light blue and n=14 for hospitalized in dark blue; total no. of 
samples 94). Solid orange lines show the linear mixed model estimate for the period 
beyond day 30. Kinetics of antibody decay (panels a-c) were calculated excluding 
timepoints preceding the maximal values for each patient. Kinetics of neutralizing 
antibodies excluded samples preceding day 30 (as in Fig 2a/b). All excluded values are 










Gender (female), n (%) 72 (68) 46 (44) 0.0006a 
Age (years), median [IQR] 46.5 [38 - 54] 57.5 [46 - 66] <0.0001b 
Individuals with 2 or more samples, n (%)   52 (49) 59 (57) 0.278a 
Wave of COVID-19 outbreak (first), n (%) 96 (91) 73 (70)  
Severity, n (%)    
         Asymptomatic 8 (8) ---  
         Mild 98 (92) ---  
         Hospitalized non-severe --- 59 (56.7)  
         Hospitalized severe --- 37 (35.6)  
         Hospitalized (intensive care unit) --- 8 (7.7)  
IQR: interquartile range (25th and 75th percentiles), a Chi square test, b Mann-Whiney test 
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